These biotech stocks are the best analysts to trust

The US stock market was mixed on Thursday but healthcare stocks gained more than 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding 0.5% on Thursday.

Wall Street analysts make new stock picks daily. Most analysts have excellent track records at anticipating market movements, but they are not all that impressive for investors. Analyst ratings and price targets can vary widely when it comes to one single stock, leaving investors confused about which analyst's opinion is to trust.

Readers can sort by stock ticker, company name, analyst firm, rating change, or other variables.

Here is a look at some of the top biotechnology stocks of several analysts, according to Benzinga Analyst Stock Ratings.

On November 17, 2022 Argus Research analyst Jasper Hellweg maintained a Buy rating on the company's stock and raised the price target from $320 to $340. Hellweg sees 6% upside in the stock and has an accuracy rate of 69%.

Barclays analyst Gena Wang reiterated an Overweight rating on the company's stock on October 28, 2022, and increased the price target from $307 to $313. Wang predicts the stock will decline over 2% and has an accuracy rate of 61%.

Morgan Stanley s analyst Matthew Harrison reiterated an Equal-Weight rating on the company's stock on November 8, 2022 and raised the price target from $194 to $203. The analyst believes that over 19% of the stock will rise, and has an accuracy rate of just 52%.

On November 4, 2022, SVB Leerink analyst Roanna Ruiz maintained an Outperform rating and raised the price target from $40 to $45. Ruiz believes that the stock will rise over 66%, but it has an accuracy rate of only 22%.